Literature DB >> 21257719

Abnormalities of the TITF-1 lineage-specific oncogene in NSCLC: implications in lung cancer pathogenesis and prognosis.

Ximing Tang1, Humam Kadara, Carmen Behrens, Diane D Liu, Yun Xiao, David Rice, Adi F Gazdar, Junya Fujimoto, Cesar Moran, Marileila Varella-Garcia, J Jack Lee, Waun Ki Hong, Ignacio I Wistuba.   

Abstract

PURPOSE: Emerging evidence suggests that aberrant expression of oncogenes contributes to development of lung malignancy. The thyroid transcription factor 1 (TITF-1) gene functions as a lineage survival gene abnormally expressed in a significant fraction of non-small cell lung cancers (NSCLC), in particular lung adenocarcinomas. EXPERIMENTAL
DESIGN: To better characterize TITF-1 abnormality patterns in NSCLC, we studied TITF-1's gene copy number using FISH and quantitative PCR, as well as its protein expression by immunohistochemistry analysis in a tissue microarray comprising surgically resected NSCLC (N = 321) including 204 adenocarcinomas and 117 squamous cell carcinomas (SCC). TITF-1 copy number and protein expression were correlated with patients' clinicopathologic characteristics, and in a subset of adenocarcinomas with EGFR and KRAS mutation status.
RESULTS: We found that increased TITF-1 protein expression was prevalent in lung adenocarcinomas only and was significantly associated with female gender (P < 0.001), never-smokers (P = 0.004), presence of EGFR mutations (P = 0.05), and better overall survival (all stages, P = 0.0478; stages I and II, P = 0.002). TITF-1 copy number gain(CNG) was detected by FISH analysis in both adenocarcinomas (18.9%; high CNG, 8.3%) and SCCs (20.1%; high CNG, 3.0%), and correlated significantly with the protein product (P = 0.004) and presence of KRAS mutations (P = 0.008) in lung adenocarcinomas. Moreover, multivariate analysis revealed that TITF-1 copy number gain was an independent predictor of poor survival of NSCLC (P = 0.039).
CONCLUSIONS: Our integrative study demonstrates that the protein versus genomic patterns of TITF-1 have opposing roles in lung cancer prognosis and may occur preferentially in different subsets of NSCLC patients with distinct oncogene mutations. ©2011 AACR.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21257719      PMCID: PMC3078948          DOI: 10.1158/1078-0432.CCR-10-1412

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  43 in total

1.  Revisions in the International System for Staging Lung Cancer.

Authors:  C F Mountain
Journal:  Chest       Date:  1997-06       Impact factor: 9.410

Review 2.  Thyroid transcription factor-1.

Authors:  C D Bingle
Journal:  Int J Biochem Cell Biol       Date:  1997-12       Impact factor: 5.085

3.  EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.

Authors:  William Pao; Vincent Miller; Maureen Zakowski; Jennifer Doherty; Katerina Politi; Inderpal Sarkaria; Bhuvanesh Singh; Robert Heelan; Valerie Rusch; Lucinda Fulton; Elaine Mardis; Doris Kupfer; Richard Wilson; Mark Kris; Harold Varmus
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-25       Impact factor: 11.205

4.  EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Authors:  J Guillermo Paez; Pasi A Jänne; Jeffrey C Lee; Sean Tracy; Heidi Greulich; Stacey Gabriel; Paula Herman; Frederic J Kaye; Neal Lindeman; Titus J Boggon; Katsuhiko Naoki; Hidefumi Sasaki; Yoshitaka Fujii; Michael J Eck; William R Sellers; Bruce E Johnson; Matthew Meyerson
Journal:  Science       Date:  2004-04-29       Impact factor: 47.728

5.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

Authors:  Thomas J Lynch; Daphne W Bell; Raffaella Sordella; Sarada Gurubhagavatula; Ross A Okimoto; Brian W Brannigan; Patricia L Harris; Sara M Haserlat; Jeffrey G Supko; Frank G Haluska; David N Louis; David C Christiani; Jeff Settleman; Daniel A Haber
Journal:  N Engl J Med       Date:  2004-04-29       Impact factor: 91.245

6.  Gene structure and expression of human thyroid transcription factor-1 in respiratory epithelial cells.

Authors:  K Ikeda; J C Clark; J R Shaw-White; M T Stahlman; C J Boutell; J A Whitsett
Journal:  J Biol Chem       Date:  1995-04-07       Impact factor: 5.157

7.  Defects in tracheoesophageal and lung morphogenesis in Nkx2.1(-/-) mouse embryos.

Authors:  P Minoo; G Su; H Drum; P Bringas; S Kimura
Journal:  Dev Biol       Date:  1999-05-01       Impact factor: 3.582

8.  The T/ebp null mouse: thyroid-specific enhancer-binding protein is essential for the organogenesis of the thyroid, lung, ventral forebrain, and pituitary.

Authors:  S Kimura; Y Hara; T Pineau; P Fernandez-Salguero; C H Fox; J M Ward; F J Gonzalez
Journal:  Genes Dev       Date:  1996-01-01       Impact factor: 11.361

9.  Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.

Authors:  George D Demetri; Margaret von Mehren; Charles D Blanke; Annick D Van den Abbeele; Burton Eisenberg; Peter J Roberts; Michael C Heinrich; David A Tuveson; Samuel Singer; Milos Janicek; Jonathan A Fletcher; Stuart G Silverman; Sandra L Silberman; Renaud Capdeville; Beate Kiese; Bin Peng; Sasa Dimitrijevic; Brian J Druker; Christopher Corless; Christopher D M Fletcher; Heikki Joensuu
Journal:  N Engl J Med       Date:  2002-08-15       Impact factor: 91.245

10.  The lung-specific surfactant protein B gene promoter is a target for thyroid transcription factor 1 and hepatocyte nuclear factor 3, indicating common factors for organ-specific gene expression along the foregut axis.

Authors:  R J Bohinski; R Di Lauro; J A Whitsett
Journal:  Mol Cell Biol       Date:  1994-09       Impact factor: 4.272

View more
  42 in total

1.  An Integrated Molecular Analysis of Lung Adenocarcinomas Identifies Potential Therapeutic Targets among TTF1-Negative Tumors, Including DNA Repair Proteins and Nrf2.

Authors:  Robert J G Cardnell; Carmen Behrens; Lixia Diao; YouHong Fan; Ximing Tang; Pan Tong; John D Minna; Gordon B Mills; John V Heymach; Ignacio I Wistuba; Jing Wang; Lauren A Byers
Journal:  Clin Cancer Res       Date:  2015-04-15       Impact factor: 12.531

2.  Lysyl hydroxylase 2 induces a collagen cross-link switch in tumor stroma.

Authors:  Yulong Chen; Masahiko Terajima; Yanan Yang; Li Sun; Young-Ho Ahn; Daniela Pankova; Daniel S Puperi; Takeshi Watanabe; Min P Kim; Shanda H Blackmon; Jaime Rodriguez; Hui Liu; Carmen Behrens; Ignacio I Wistuba; Rosalba Minelli; Kenneth L Scott; Johannah Sanchez-Adams; Farshid Guilak; Debananda Pati; Nishan Thilaganathan; Alan R Burns; Chad J Creighton; Elisabeth D Martinez; Tomasz Zal; K Jane Grande-Allen; Mitsuo Yamauchi; Jonathan M Kurie
Journal:  J Clin Invest       Date:  2015-02-09       Impact factor: 14.808

3.  Associations of deregulation of mir-365 and its target mRNA TTF-1 and survival in patients with NSCLC.

Authors:  Ruifang Sun; Zhigang Liu; Gang Ma; Weidong Lv; Xinliang Zhao; Guangyan Lei; Changfu Xu
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

4.  ASCL1 is a lineage oncogene providing therapeutic targets for high-grade neuroendocrine lung cancers.

Authors:  Alexander Augustyn; Mark Borromeo; Tao Wang; Junya Fujimoto; Chunli Shao; Patrick D Dospoy; Victoria Lee; Christopher Tan; James P Sullivan; Jill E Larsen; Luc Girard; Carmen Behrens; Ignacio I Wistuba; Yang Xie; Melanie H Cobb; Adi F Gazdar; Jane E Johnson; John D Minna
Journal:  Proc Natl Acad Sci U S A       Date:  2014-09-29       Impact factor: 11.205

5.  Cisplatin sensitivity mediated by NKX2-1 in lung adenocarcinoma is dependent on p53 mutational status via modulating TNFSF10 expression.

Authors:  Ming-Jenn Chen; Po-Ming Chen; Lee Wang; Ching-Ju Shen; Chi-Yi Chen; Huei Lee
Journal:  Am J Cancer Res       Date:  2020-04-01       Impact factor: 6.166

6.  Expression of VEGFR2 and NRP-1 in non-small cell lung cancer and their clinical significance.

Authors:  Manhua Ding; Liang Liu; Chengxi Hu; Yi Liu; Yun Qiao; Xiaodong Jiang
Journal:  Chin J Cancer Res       Date:  2014-12       Impact factor: 5.087

7.  Cancer genes in lung cancer: racial disparities: are there any?

Authors:  Ahmed El-Telbany; Patrick C Ma
Journal:  Genes Cancer       Date:  2012-07

8.  ETS2 mediated tumor suppressive function and MET oncogene inhibition in human non-small cell lung cancer.

Authors:  Ignacio I Wistuba; Humam Kadara; Mohamed Kabbout; Melinda M Garcia; Junya Fujimoto; Diane D Liu; Denise Woods; Chi-Wan Chow; Gabriela Mendoza; Amin A Momin; Brian P James; Luisa Solis; Carmen Behrens; J Jack Lee
Journal:  Clin Cancer Res       Date:  2013-05-09       Impact factor: 12.531

9.  Thyroid transcription factor-1 expression is an independent predictor of recurrence and correlates with the IASLC/ATS/ERS histologic classification in patients with stage I lung adenocarcinoma.

Authors:  Kyuichi Kadota; Jun-Ichi Nitadori; Inderpal S Sarkaria; Camelia S Sima; Xiaoyu Jia; Akihiko Yoshizawa; Valerie W Rusch; William D Travis; Prasad S Adusumilli
Journal:  Cancer       Date:  2012-10-23       Impact factor: 6.860

10.  EZH2 protein expression associates with the early pathogenesis, tumor progression, and prognosis of non-small cell lung carcinoma.

Authors:  Carmen Behrens; Luisa M Solis; Heather Lin; Ping Yuan; Ximing Tang; Humam Kadara; Erick Riquelme; Hector Galindo; Cesar A Moran; Neda Kalhor; Stephen G Swisher; George R Simon; David J Stewart; J Jack Lee; Ignacio I Wistuba
Journal:  Clin Cancer Res       Date:  2013-10-04       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.